Valuation: Aquestive Therapeutics, Inc.

Market Cap 553M 479M 449M 410M 771M 52.77B 784M 5.26B 2.06B 26.41B 2.08B 2.03B 88.12B P/E 2026 *
-10.9x
P/E 2027 * -11.4x
Enterprise Value 468M 406M 380M 347M 652M 44.67B 663M 4.45B 1.75B 22.36B 1.76B 1.72B 74.59B EV / Sales 2026 *
9.27x
EV / Sales 2027 * 7.69x
Free-Float
96.94%
Yield 2026 *
-
Yield 2027 * -
1 day+2.80%
1 week+17.91%
Current month+19.35%
1 month+7.04%
3 months+1.61%
6 months+15.45%
Current year-31.73%
1 week 3.76
Extreme 3.76
4.69
1 month 3.56
Extreme 3.56
4.69
Current year 2.93
Extreme 2.93
6.59
1 year 2.93
Extreme 2.93
7.55
3 years 1.25
Extreme 1.2514
7.55
5 years 0.62
Extreme 0.618
7.55
10 years 0.62
Extreme 0.618
20.7
Manager TitleAgeSince
Chief Executive Officer 50 17/05/2022
Director of Finance/CFO 67 31/12/2020
Compliance Officer - 02/04/2026
Director TitleAgeSince
Chairman 72 01/04/2024
Director/Board Member 60 01/01/2004
Director/Board Member 50 17/05/2022
Date Insider Type Main position Quantity % Market Cap.
16/07/26 Sell

Chief Executive Officer

-20,369 0.0162%
09/03/26 Free

General Counsel

200,311 0.1642%
09/03/26 Other

Chief Operating Officer

168,291 0.1379%
Change 5-day change 1-year change 3-year change Capi.($)
+2.80%+17.91%+14.25%+127.32% 538M
-1.37%+8.90%+91.28%+130.00% 1,098B
-0.77%+1.91%+49.46%+49.44% 631B
+0.85%+2.58%+25.90%+64.34% 438B
-1.13%+3.13%+49.78%+39.13% 368B
-0.74%+1.01%+31.08%+38.64% 298B
-1.22%+0.89%+7.32%+7.38% 251B
-0.70%+6.23%+45.32%+57.82% 226B
+0.34%-0.13%-4.77%-50.50% 209B
+2.04%+0.38%+12.70%+69.71% 165B
Average +0.01%+1,496.73%+32.23%+53.33% 368.49B
Weighted average by Cap. -0.63%+1,339.35%+49.81%+66.20%

Financials

2026 *2027 *
Net sales 50.51M 43.77M 40.98M 37.39M 70.36M 4.82B 71.55M 481M 188M 2.41B 190M 186M 8.04B 71.92M 62.32M 58.34M 53.24M 100M 6.86B 102M 684M 268M 3.43B 270M 264M 11.45B
Net income -50.65M -43.89M -41.09M -37.49M -70.55M -4.83B -71.74M -482M -189M -2.42B -190M -186M -8.07B -47.99M -41.59M -38.94M -35.53M -66.86M -4.58B -67.98M -457M -179M -2.29B -180M -176M -7.64B
Net Debt -85M -73.66M -68.96M -62.92M -118M -8.11B -120M -809M -317M -4.06B -319M -312M -13.54B -
Logo Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Employees
147
Date Price Change Volume
11/08/26 $4.410 +2.80% 6,482,911
10/08/26 $4.290 +8.88% 7,295,514
07/08/26 $3.940 +0.51% 1,860,430
06/08/26 $3.920 +4.39% 1,536,412
05/08/26 $3.755 +0.40% 1,466,033
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
4.410USD
Average target price
9.222USD
Spread / Average Target
+109.12%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AQST Stock